Skip to main content

Advertisement

Table 2 Follow-up and final disposition of subjects a

From: A novel serogenetic approach determines the community prevalence of celiac disease and informs improved diagnostic pathways

  Women, n Men, n
Total subjects 1,390 1,158
CD diagnosed by histology before enrolment 0 1
Abnormal composite TG2/DGP IgA/IgG, and TG2 IgA, or DGP IgA or IgG 51 56
Findings diagnostic/supportive of untreated CD   
 Histological diagnosis: Intestinal villous atrophy, crypt hyperplasia, and IELs   
  Prompted by current study, 2010 6 4
  During standard medical care between 2004 and 2009 4 2
 Serological diagnosis: confirmation of multiple CD serological abnormalities   
  No supporting histological evidence obtained 2 3
  Treating doctor excluded CD because patient was asymptomatic 0 2
Findings equivocal for CD   
 Intestinal IELs +/− mild focal villous atrophy, or villous atrophy and crypt hyperplasia without IELs 0 3
Findings excluded/were not supportive of CD   
 Normal intestinal histology without serological testing 2 5
 Serological exclusion: CD serological abnormalities not replicated 7 8
 Genotyping exclusion: testing for HLA DQ2.5/8/2.2 negative 0 1
Follow-up not possible or not undertaken   
 Treating doctor did not investigate further as subject asymptomatic and/or performed blood tests unrelated to CD 1 5
 Subject deceased and CD not diagnosed pre-mortem 8 5
 Subject declined follow-up medical review 16 11
 Subject could not be contacted; lost to follow-up 5 7
CD cases estimated by serogenetic modeling, range 12 to 26 12 to 16
Lower 95% CI for CD cases based on TG2+ EMA+ 11 12
  1. Abbreviations: CD, celiac disease; DGP, Deamidated gliadin-derived peptide; EMA, endomysial antibody; HLA, human leukocyte antigen; IEL, Intra-epithelial lymphocyte; Ig, immunoglobulin; TG, transglutaminase.
  2. aData are n, unless otherwise stated.